Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) FCF Margin (2017 - 2025)

VYNE Therapeutics' FCF Margin history spans 9 years, with the latest figure at 10764.0% for Q2 2025.

  • For Q2 2025, FCF Margin fell 652300.0% year-over-year to 10764.0%; the TTM value through Dec 2025 reached 8155.61%, down 138828.0%, while the annual FY2025 figure was 5811.23%, 100657.0% up from the prior year.
  • FCF Margin reached 10764.0% in Q2 2025 per VYNE's latest filing, down from 5750.0% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 3669.6% in Q4 2021 to a low of 16589.66% in Q4 2022.
  • Average FCF Margin over 5 years is 7445.29%, with a median of 6138.89% recorded in 2022.
  • Peak YoY movement for FCF Margin: plummeted -1292006bps in 2022, then skyrocketed 983044bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 3669.6% in 2021, then plummeted by -352bps to 16589.66% in 2022, then soared by 59bps to 6759.21% in 2023, then plummeted by -60bps to 10809.64% in 2024, then increased by 0bps to 10764.0% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's FCF Margin are 10764.0% (Q2 2025), 5750.0% (Q1 2025), and 10809.64% (Q4 2024).